Neurogene Inc (NGNE) Stock Forecast & Price Target
Neurogene Inc (NGNE) Analyst Ratings
Bulls say
Neurogene Inc is demonstrating improved confidence in its pipeline, particularly with its lead candidate NGN-401 for Rett syndrome, supported by enhancements in managing HLH reactions through better monitoring techniques. The company’s proprietary EXACTTM technology positions it well in the competitive landscape of genetic medicines for rare neurological diseases, which presents a significant market opportunity given the high unmet medical needs in this area. Consequently, positive developments in clinical trials and management capability have contributed to an optimistic outlook for Neurogene's operational and financial performance.
Bears say
Neurogene Inc's financial outlook is adversely affected by the potential clinical failure of its key drug candidates, which could severely disrupt the company's ability to raise necessary capital for continued operations and development. Additionally, negative investor sentiment regarding drug pricing, mergers and acquisitions, and overall sector valuations could further diminish the company's market valuation. The outlined downside scenario suggests that if Neurogene fails to establish a credible registrational trial or encounters safety concerns, the repercussions could significantly impact its stock performance, with projections indicating a potential drop to $8.
This aggregate rating is based on analysts' research of Neurogene Inc and is not a guaranteed prediction by Public.com or investment advice.
Neurogene Inc (NGNE) Analyst Forecast & Price Prediction
Start investing in Neurogene Inc (NGNE)
Order type
Buy in
Order amount
Est. shares
0 shares